Press release

Corindus Equips the World’s First Fully Robotic Catheterization Laboratory

Sponsored by Businesswire

Vascular Robotics, Inc.
(“Corindus” or the “Company”) (NYSE
American: CVRS), a leading developer of precision vascular robotics,
announced today that Chesapeake Regional Healthcare in Chesapeake, VA
has equipped both of its catheterization labs at Chesapeake Regional
Medical Center with CorPath GRX Vascular Robotic Systems, making it the
first hospital in the world to adopt vascular robotic systems in all
vascular intervention treatment rooms. The outfitted labs will allow
physicians to leverage the latest robotic technology for percutaneous
coronary intervention (PCI) and peripheral vascular intervention (PVI)
and provide all patients requiring these procedures at Chesapeake
Regional access to the latest technology in cardiovascular disease care.

“Through a full commitment to our technology, Chesapeake Regional
Medical Center has positioned itself as a premier vascular treatment
facility in the U.S.,” said Mark Toland, President and Chief Executive
Officer of Corindus. “Just a few months after their first CorPath GRX
purchase, strong physician demand led to the purchase of a second
system, offering all of their patients suffering from heart disease the
option of robotic treatment. In addition, more physicians are opting to
treat their patients at Chesapeake Regional to provide them with the
benefits of robotics and the most advanced treatment options available.
We want to congratulate Chesapeake Regional on this landmark achievement
and for embracing robotic-assisted procedures to enhance patient care,”
added Toland.

The multi-system installation addresses the needs and demands of the
physicians, staff, and patients. The center is the first non-academic
hospital in the state of Virginia to launch a vascular robotic program
and perform a robotic-assisted PCI procedure using the CorPath GRX
System, and is the first facility in the world with vascular robotic
capabilities in all catheterization labs. Ronald McKechnie, MD, Medical
Director of the Catheterization Lab at Chesapeake Regional Medical
Center, performed the organization’s first robotic-assisted PCI
procedure on March 18, 2019.

“Since installing our first system, we have taken pride in providing our
patients with access to the most advanced treatment options, while also
providing our physicians and staff protection from the daily
occupational hazards involved with vascular intervention,” said Dr.
McKechnie. “Technological advances like these will not only improve
outcomes for our patients, but also change the landscape for the future
treatment of cardiovascular disease everywhere. Patients are seeking
robotic technology for coronary care and we are thrilled to be a part of
this movement.”

To learn more about Corindus and CorPath GRX, please visit

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics is a global technology leader in
robotic-assisted vascular interventions. The Company’s CorPath® platform
is the first FDA-cleared medical device to bring robotic precision to
percutaneous coronary and vascular procedures. CorPath GRX is the second
generation robotic-assisted technology offering enhancements to the
platform by adding important key upgrades that increase precision,
improve workflow, and extend the capabilities and range of procedures
that can be performed robotically. We are focused on developing
innovative robotic solutions to revolutionize treatment of emergent
conditions by providing specialized and timely medical care to patients
around the world. For additional information, visit,
and follow @CorindusInc.

About Chesapeake Regional Healthcare

Chesapeake Regional Healthcare is home to Chesapeake Regional Medical
Center, the only independent, community-based hospital in the Hampton
Roads region providing technologically advanced health care to the
residents of southeastern Virginia and northeastern North Carolina for
more than 40 years. It offers a nationally accredited Chest Pain Center,
a Bariatric Surgery Center of Excellence, several five-star ratings from
Healthgrades® and one of the busiest Emergency Departments and maternity
wards in the area. With more than 600 physicians on staff, the first da
Vinci® XI Surgical System in the state of Virginia and the first
hospital in the world to adopt CorPath GRX Vascular Robotic Systems in
all vascular intervention treatment rooms, Chesapeake Regional is
dedicated to putting patients first with the most advanced treatments in
health care and a personalized touch. For more information, visit

Forward Looking Statements

Statements made in this release that are not statements of historical or
current facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements may involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of Corindus to be materially different from historical results or from
any future results or projections expressed or implied by such
forward-looking statements. Accordingly, readers should not place undue
reliance on any forward-looking statements. In addition to statements
that explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as “believes,” “belief,” “expects,” “estimates,”
“intends,” “anticipates” or “plans” to be uncertain and forward-looking.
Forward-looking statements may include comments as to Corindus’ beliefs
and expectations as to future events and trends affecting its business
and are necessarily subject to uncertainties, many of which are outside
Corindus’ control.

Examples of such statements include statements regarding or such as:

  • More physicians are opting to treat their patients at Chesapeake
    Regional to provide them with the benefits of robotics and the most
    advanced treatment options available.
  • Technological advances like these will not only improve outcomes for
    our patients, but also change the landscape for the future treatment
    of cardiovascular disease everywhere.

Important factors that could cause actual results to differ materially
from those indicated by such forward-looking statements are described in
the sections titled “Risk Factors” in the Company’s filings with the
Securities and Exchange Commission, including its most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as
reports on Form 8-K, including, but not limited to the following: our
ability to expand our technology platform and achieve the advances
necessary for telestenting and remote procedures, including in humans;
our ability to expand our technology platform for use in other segments
of the vascular intervention market, including neurointerventional and
other more complex cardiac interventions; obtaining necessary regulatory
approvals for the use on humans and marketing of our products in the
United States and in other countries, including for stroke and other
neurovascular interventions; the rate of adoption of our CorPath System
and the rate of use of our cassettes; risks associated with market
acceptance, including pricing and reimbursement; our ability to enforce
our intellectual property rights; our need for additional funds to
support our operations; our ability to manage expenses and cash flow;
factors relating to engineering, regulatory, manufacturing, sales and
customer service challenges; potential safety and regulatory issues that
could slow or suspend our sales; and the effect of credit, financial and
economic conditions on capital spending by our potential customers.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More information
is available on Corindus’ website at